BioLineRx (BLRX) Announces Positive Preliminary Results from Phase I Clinical Trial of BL-1021 for Neuropathic Pain

BioLineRx (NASDAQ: BLRX) (TASE: BLRX) announced today the last visit of the last subject and preliminary results of the Phase Ia study of BL-1021, an orally available small molecule for neuropathic pain. Study results demonstrated that a single administration of BL-1021 was safe and well tolerated. In addition, preliminary modeling of the pharmacokinetic data collected in this trial predicts that a once daily administration of BL-1021 at the dose levels assessed in the trial will enable reaching effective doses in patients. Final results are expected to be announced in the fourth quarter of 2011.

The trial was a first-in-human, double-blind, placebo-controlled study performed at the Hadassah Clinical Research Center, Jerusalem, Israel. The study aimed at assessing the safety, tolerability and pharmacokinetics (PK) of a single administration of BL-1021 at doses between 10 mg and 80 mg.

Dr. Kinneret Savitsky, BioLineRx’s CEO, stated, “This Phase I trial has demonstrated the safety and tolerability of BL-1021 and we believe it has the potential to provide improved efficacy without the side effects associated with many existing medications. We are also encouraged by the favorable pharmacokinetic profile of BL-1021 and anticipate that the final results and analysis will confirm that BL-1021 has the competitive advantage of a once daily administration. This trial is an important milestone towards the commercialization of BL-1021.”

About BL-1021

BL-1021 is an orally available small molecule for the treatment of neuropathic pain that was designed to share the activities of anti-neuropathic drugs without their common adverse effects. BL-1021’s efficacy has been demonstrated in various animal models of neuropathic pain. Pre-clinical data demonstrate that BL-1021 has a lowered propensity for sedation, low cardiac toxicity and improved efficacy compared with other anti-pain medications.

About Neuropathic Pain

Neuropathic pain is a complex, chronic state of pain that results from dysfunctional or injured nerve fibers. Neuropathic pain is associated with various conditions, including shingles, diabetes and cancer and is reported to affect 1% to 3% of the population. Patients describe the symptoms as burning, stabbing, electric shock or itching sensations, which can cause extreme discomfort for extended periods of time. A variety of medications are used to treat neuropathic pain, including antidepressants and anti-seizure medicines. However, these medications have significant side effects and are not always effective. In 2009 the neuropathic pain market was estimated to be $2.4 billion in the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK), and it is projected to grow to $4.1 billion in 2018.

About BioLineRx

BioLineRx Ltd. is a publicly-traded biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. BioLineRx’s current portfolio consists of five clinical stage candidates: BL-1020 for schizophrenia is in Phase II/III clinical trials; BL-1040 for treatment of patients following a myocardial infarction has completed a Phase I/II study and has been out-licensed to Ikaria Inc. for a total deal value of $282.5 million, in addition to sales royalties; BL-5010 for non-surgical removal of skin lesions has completed a Phase I/II study; BL-1021 for neuropathic pain is in Phase I trials; and BL-7040 for treating Inflammatory Bowel Disease (IBD) has completed Phase I. In addition, BioLineRx has nine products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases.

BioLineRx’s business model is based on acquiring molecules mainly from biotechnological incubators and academic institutions. The Company performs feasibility assessment studies and development through pre-clinical and clinical stages, with partial funding from the Israeli Government’s Office of the Chief Scientist (OCS). The final stage includes partnering with medium and large pharmaceutical companies for advanced clinical development (Phase III) and commercialization. For more information on BioLineRx, please visit www.biolinerx.com.

The estimates and judgments with respect to the projects included in this release are considered forward-looking statements, which involve certain risks and uncertainties, and are based on information available to the Company at the time of this release. Such estimates may not be realized or may be only partially realized, due to the significant uncertainty characterizing research and development activities in general, particularly those of drug development, including changes in regulation or uncertainty relating to the application of regulation, unexpected delays in obtaining regulatory approval, unexpected delays in patient recruitment for clinical trials, unexpected delays in other clinical trial preparatory activities, inefficiencies, inability to manufacture, toxicity, a high level of risk/reward in comparison to current treatments available, as well as new information regarding intellectual property rights which may affect the economic viability of continued product development. The Company assumes no responsibility for updating forward-looking statements made herein or otherwise.

Multi Million Ounce Gold Resource Defined at Paramount Gold’s (PZG) Sleeper Project in Nevada

NovaBay Pharmaceuticals (NBY) Reports Positive Results in Sinus Infection Study

EMERYVILLE, Calif., Sept. 12, 2011 (GLOBE NEWSWIRE) — NovaBay^® Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company developing its first-in-class, anti-infective Aganocide^® compounds for the local non-systemic treatment and prevention of antibiotic-resistant infections, presented a new study reporting results of its Aganocide compound NVC-422 for the treatment of sinusitis in a sheep model.

The study, titled “Efficacy of NVC-422 Against Staphylococcus aureus Biofilms in a Sheep Model of Sinusitis,” was conducted by Professor P.J. Wormald and his research team from the University of Adelaide in Australia in collaboration with researchers at NovaBay. It was presented at the 2011 meeting of the American Rhinologic Society in San Francisco on September 10.

In this study the sheep frontal lobe sinuses were infected with staph aureus. The infection was allowed to form a biofilm to develop over a seven day period. Two concentrations of NVC-422 (0.1% and 0.5%) were used in the study drug treatment group while the controls were treated with normal saline or vehicle control. The results showed that nasal irrigation with the study drug NVC-422 effectively reduced the S. aureus biomass with the 0.5% being more effective without adverse events.

Ron Najafi, CEO of NovaBay, stated: “These results from the team at the University of Adelaide are very encouraging and add to the portfolio of important results with our lead Aganocide compound NVC-422. This study was observed to reduce bacterial biofilm mass in a dose-dependent manner. Further research will clarify our understanding of NVC-422’s specific abilities to reduce the incidence of biofilms, and its possible use in treating humans with antibiotic-resistant chronic sinusitis.

About Sinus Infections (Sinusitis)

Sinusitis is an ailment marked by an inflammation of the paranasal sinuses, often as a consequence of a bacterial infection. Infections with the formation of a bacterial biofilm account for many cases of antibiotic-resistant chronic sinusitis. When a biofilm forms on an infection, treatment becomes very complicated, since the bacteria inside it exists in a state that renders it largely immune to antibiotics. The American Academy of Allergy, Asthma and Immunology reports that sinusitis is one of the leading forms of chronic disease, with an estimated 18 million cases and at least 30 million courses of antibiotics in the United States per year.

About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals is a clinical-stage biotechnology company focused on developing its proprietary and patented Aganocide compounds. These are novel, synthetic anti-infectives with activity against bacteria, fungi and viruses, and are being developed to treat and prevent a wide range of local, non-systemic infections with a low likelihood of developing bacterial resistance.

NovaBay is focusing its technology on four distinct therapeutic areas: dermatology, ophthalmology, urology and hospital infections. In dermatology, the focus is on developing an NVC-422 gel formulation for the highly contagious skin infection of impetigo. NovaBay has the advantage of being partnered with Galderma, the leading dermatology company in the world. In ophthalmology, the goal is to develop an eye drop for viral conjunctivitis. In urology, NovaBay aims to reduce the incidence of urinary catheter blockage and encrustation (UCBE) and the potential for urinary tract infections with an irrigation solution containing NVC-422. In hospital infection, NovaBay is targeting the six-million-patient market of chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers with its proprietary anti-infective solution, NeutroPhase^®, which has received two 510(k) clearances from the Food and Drug Administration. For additional information, visit www.novabaypharma.com.

Cautionary Information Regarding Forward-Looking Statements

The statements in this press release regarding NovaBay’s expectation on the potential efficacy of Aganocide compounds; the potential to develop a treatment for sinusitis as well as other statements that relate to future events or results are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward- looking statements reflect the views of the management of NovaBay as of the date of this press release and are based on assumptions and subject to significant risks and uncertainties (many of which are outside of NovaBay’s control), including, but are not limited to: the risk that results obtained in preclinical studies may not be obtained in humans; NovaBay’s Aganocide compounds may not prove to be effective in treating sinusitis; and the FDA or other regulatory agencies may delay clinical trials, or require additional studies or procedures, which could delay or prevent the development of Aganocide compounds. These and other risks relating to the development of Aganocide compounds are detailed in NovaBay’s filings with the Securities and Exchange Commission, including in the section entitled “Risk Factors” in Item 1A of Part II of that report, which was filed with the Securities and Exchange Commission on August 10, 2011. The forward-looking statements in this press release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

CONTACT: Investors:
         NovaBay Pharmaceuticals, Inc.
         Thomas J. Paulson, Chief Financial Officer
         510-899-8809
         tjpaulson@NovaBaypharma.com

         Investors and Media:
         The Investor Relations Group
         Investor Relations:
         Adam Holdsworth
         212-825-3210
         adam@investorrelationsgroup.com
         Public Relations:
         Laura Colontrelle
         212-825-3210
         laura@investorrelationsgroup.com

RADCOM (RDCM) Wins Strategic Deal With Leading Mobile International Group

RADCOM Ltd. (NASDAQ: RDCM) a leading network service assurance provider, today announced that it has received additional orders totaling approximately $US 6.5 million from one of Latin America’s major multinational mobile telecommunications groups. These orders were placed by several of the group’s regional operators.

RADCOM’s rising business from this group reflects the customer’s decision to standardize on RADCOM’s advanced Omni-Q as a comprehensive solution for controlling many aspects of service quality. This deal is an integral part of RADCOM’s strategy of building relationships with multi-national telecommunications groups that can implement RADCOM’s unique tools across their operators. Since this operator is one of the most advanced operators in Latin America, RADCOM’s comprehensive offering is ideal for them, as RADCOM can provide one platform for all technologies on their network. RADCOM’s focused offerings for cross-national operators, such as interconnection management and roaming analysis were significant features in this operator’s decision to choose RADCOM as the preferred solution.

“This strategic deal by this multi-national group improves our visibility, making us even more confident in our product and marketing strategy,” commented Mr. David Ripstein, RADCOM’s President and CEO. “These deals confirm that we are well positioned with the right technology, in a high-potential market.”

About RADCOM

RADCOM develops, manufactures, markets and supports innovative network test and service monitoring solutions for communications service providers and equipment vendors. The Company specializes in next-generation Cellular as well as IMS, Voice, Data and VoIP networks. Its solutions are used in the development and installation of network equipment and in the maintenance of operational networks. The Company’s products facilitate fault management, network service performance monitoring and analysis, troubleshooting and pre-mediation. RADCOM’s shares are listed on the NASDAQ Capital Market under the symbol RDCM. For more information, please visit http://www.RADCOM.com.

Risks Regarding Forward-Looking Statements

Certain statements made herein that use words such as “estimate,” “project,” “intend,” “expect,” “‘believe”, “may”, “might”, “predict”, “potential”, “anticipate”, “plan” or similar expressions are intended to identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties that could cause the actual results, performance or achievements of RADCOM to be materially different from those that may be expressed or implied by such statements, including, among others, changes in general economic and business conditions and specifically, decline in the demand for RADCOM’s products, inability to timely develop and introduce new technologies, products and applications, and loss of market share and pressure on prices resulting from competition. For additional information regarding these and other risks and uncertainties associated with the RADCOM’s business, reference is made to RADCOM’s reports filed from time to time with the United States Securities and Exchange Commission. RADCOM does not undertake to revise or update any forward-looking statements for any reason.

Contact:
Eyal Harari
VP Products and Marketing
+972-77-774-5030
eyalh@radcom.com

SOURCE RADCOM Ltd

MicroVision (MVIS) Demonstrates the Future of Mobile 3D Displays

MicroVision, Inc. (NASDAQ: MVIS), the leader in innovative ultra-miniature laser display technology, today is demonstrating an early version of its 3D PicoP® prototype during the Visions of the Future session at Mobile Future Forward in Seattle. Sid Madhavan, vice president of R&D and applications, will share more details on the 3D technology developed by MicroVision at the event.

MicroVision’s 3D PicoP utilizes a mixed-polarization approach with its laser scanning technology to deliver 60Hz frame rates to each eye, enabling the use of less expensive passive 3D eyewear. This allows MicroVision to offer a cost-effective and pocket-sized mobile solution, compared to competitive approaches that utilize two projectors or bulky and more expensive active shutter glasses.

As more 3D content becomes available on a growing range of devices, from smartphones to handheld gaming consoles, users would have the ability to break free from small screens and leverage 3D PicoP to display content over 100 inches in diagonal image size. In addition, MicroVision’s in-motion laser display technology is ideal for high intensity, action-packed 3D mobile games, providing focus-free crisp images for extremely immersive experiences.

“MicroVision technology makes it easier for consumers to view, share, collaborate and play games, using mobile devices that they simply don’t leave home without,” said Alexander Tokman, president and CEO, MicroVision. “3D on the move is a next logical step, and we are uniquely positioned to take the immersive 3D viewing experience beyond the living room.”

Original equipment manufacturers would be able to leverage the 3D technology in MicroVision’s next-generation HD PicoP engine that is expected to be released during the second half of 2012.

About MicroVision

MicroVision provides the PicoP display technology platform designed to enable next-generation display and imaging products for pico projectors, vehicle displays and wearable displays that interface with mobile devices. The company’s PicoP display engine uses highly efficient laser light sources that create vivid images with high contrast and brightness. For more information, visit us on:

Our company website: microvision.com
Our corporate blog: microvision.com/displayground
Twitter: twitter.com/microvision
Facebook: facebook.com/MicrovisionInc
YouTube: youtube.com/mvisvideo

PicoP is a registered trademark of MicroVision Inc. in the United States and other countries. All other trademarks are the properties of their respective owners.

Forward-Looking Statements

Certain statements contained in this release, including those relating to future availability of 3D technology and products, future product development and those using words such as “would” are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company’s forward-looking statements include the following: our ability to raise additional capital when needed; our or our customers failure to perform under open purchase orders; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market our products; potential product liability claims; and other risk factors identified from time to time in the company’s SEC reports, including the company’s Annual Report on Form 10-K filed with the SEC. Except as expressly required by federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changes in circumstances or any other reason.

T3 Motion (TTTM) Expands International Footprint of its Electric Vehicles into Saudi Arabia

Global Industries (GLBL) Signs Merger Agreement with Technip

Entropic Communications (ENTR), Technetix Deliver MoCA to the European Market

AMSTERDAM, Sept. 9, 2011 (GLOBE NEWSWIRE) — (IBC2011; Stand 3.A41) — Entropic Communications, Inc. (Nasdaq:ENTR), a leading provider of silicon and software solutions to enable connected home entertainment, is proud to announce European designer and manufacturer of leading technology solutions, Technetix, will bring the first ever push-on Ethernet-to-Coax Network Adapter (TECB-D01), powered by Entropic’s MoCA^® (Multimedia over Coax)-based silicon solution, to the European market.

Adoption of MoCA as the leading home networking backbone topology continues to gain traction. In the U.S., MoCA is currently being deployed by service providers representing nearly 70 percent of the 100 million pay-TV homes. The opportunity in Europe is beginning to take hold as consumer demands evolve for services such as broadband extension for every room in the house, shared planning of high definition (HD) content, or multi-room digital video recording (MR-DVR), and greater interest to supporting multiple streams of HD video throughout the home.

The Technetix TECB-D01 is a single port Ethernet to coax adapter powered by Entropic’s leading MoCA-based silicon and software. The device is unique in that it provides a straightforward plug-and-play installation onto an existing home coaxial wall socket to create a high-speed, whole-home entertainment backbone. By leveraging MoCA as the basis for the home network, consumers gain the most reliable home entertainment experience, and service providers can offer enough capacity and support for streaming high volumes of whole-home HD multimedia content.

“The European market has high demand for technology solutions that can improve the performance and ease the installation of in-home entertainment networks,” said Jan Ariesen, vice president, Development Engineering, Technetix. “Our TECB-D01, based on Entropic’s leading MoCA silicon, leverages their global successes as seen from U.S. service providers and demonstrates the highest quality capabilities required to deliver the most robust and dependable in-home video and content distribution system.”

“Partnering with Technetix is a significant win for Entropic and the MoCA standard, as it strongly positions MoCA to be the network backbone technology for achieving greater penetration and expansion throughout Europe,” said Vinay Gokhale, senior vice president, Marketing and Business Development, Entropic Communications. “We see that European consumers want to deploy more HD streaming services – from shared planning to over-the-top video – throughout the home, but to gain the best viewing experience, they need bandwidth characteristics that only a MoCA network can provide.

With the availability of the TECB-D01 MoCA-based network adapter, European service providers gain an opportunity to offer more advanced, high-bandwidth IP streaming services that leverage the extremely reliable, high throughput connection that is offered by Entropic’s MoCA 1.1 technology. Additionally, as service providers rollout MoCA 2.0, the next-generation of the standard, the TECB-D01 will be fully interoperable with new MoCA 2.0 investments, allowing for the seamless deployment of new operator services.

The sister product to the TECB-D01, the Technetix TECB-01 MoCA network adapter, was awarded ‘Best Connected Home Communications Hub’ at the Connected Home Global Summit 2011 earlier this year. Both devices will go into trials with leading European service providers in 2011, and will be showcased during IBC2011 at the Entropic Stand A41-Hall 3, September 9-13, 2011, at the RAI Amsterdam.

About Technetix

Technetix designs and manufactures leading technology solutions that span the total high-speed broadband network. Driven by increasing demand for media-rich content, the broadband cable market is growing exponentially. Technetix’ market leading, critical technology enables major cable operators worldwide to increase their network capacity, improve operating efficiency and reduce costs.

Technetix supplies leading broadband cable and telecommunications suppliers worldwide such as Virgin Media, Comcast, Liberty Global, France Telecom, Ziggo and ONO. For further information, visit www.technetix.com or email sales@technetix.com

About Entropic Communications

Entropic Communications, Inc. (Nasdaq:ENTR) is a leading fabless semiconductor company that is engineering the future of connected home networking and entertainment by providing next-generation silicon and software technologies to the world’s leading cable, telco and satellite service providers, OEMs and consumer electronics manufacturers. As a co-founder of MoCA (Multimedia over Coax Alliance), Entropic pioneered and continues to evolve the way high-definition television-quality video and other multimedia and digital content such as movies, music, games and photos are brought into and delivered throughout the home. For more information, visit Entropic at www.entropic.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature constitute “forward-looking statements.” Such statements include, but are not limited to, statements regarding Entropic’s MoCA^® technology, its related prospects, and its role in the future of home networking. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause Entropic’s actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, the effects of competition, risks associated with Entropic’s dependence on a limited number of customers and suppliers, technology risks, the risk that the market for HD video and multimedia content delivery solutions may not develop as Entropic anticipates, and other factors discussed in the “Risk Factors” section of Entropic’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2011. All forward-looking statements are qualified in their entirety by this cautionary statement. Entropic is providing this information as of the date of this release and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Technetix and the Technetix logo are trademarks or registered trademarks of Technetix Group Limited in the UK and certain other countries. MoCA is a registered trademark of the Multimedia Over Coax Alliance.

CONTACT: Entropic Contacts:
         Investor Contact:
         Debra Hart
         Director, Investor Relations
         +1 858-768-3852
         debra.hart@entropic.com

         Media Contacts:
         Robbin Lynn
         Marketing Communications Manager
         +1 760-579-2261
         robbin.lynn@entropic.com

         Chris Fallon
         Ruder Finn for Entropic Communications
         +1 917-974-1667
         fallonc@ruderfinn.com

         Technetix Contacts:
         Steve Farrell
         Product Management Director
         +44 (0) 1444 251 208
         steve.farrell@technetix.com

         Annette Unsworth
         Technical Publications Manager
         +44 (0) 1444 251 245
         annette.unsworth@technetix.com

Charm Communications (CHRM) to Present at Susquehanna Financial Group’s Fifth Annual Beijing Management Summit

First Merchants Corporation (FRME) Announces $21.2 Million Capital Raise

First Merchants Corporation (NASDAQ: FRME), announced that it has raised $21.2 million in a direct private placement of its common stock. First Merchants also announced that it has received preliminary approval to receive an investment of approximately $90.8 million in the Company’s preferred stock through the Small Business Lending Fund (SBLF). First Merchants intends to utilize the proceeds from the private placement and participation in the SBLF program to fully repay the United States Treasury Department’s $116 million investment in First Merchants through its TARP Capital Purchase Program.

Mark Hardwick, Chief Financial Officer said, “First Merchants is thankful for the ability to participate in the TARP program as it helped the Corporation weather the recent recession. However, management and the Board of Directors are very pleased to be repaying the investment in full.” Hardwick also added, “The private equity offering, which closed at $7.50 per share, a premium to last night’s closing price, positively complements an already enhanced capital structure when compared to pre-recession levels. The execution of this transaction is reflective of the confidence our new institutional investors have in the growth strategy of First Merchants.”

The primary catalyst behind the repayment of TARP was First Merchants’ preliminary approval to participate in the Small Business Lending Fund (SBLF) as created by the 2010 Small Business Jobs Act. The SBLF is a new lending program that encourages qualified community banks to partner with small businesses and entrepreneurs to create jobs and promote economic development in local communities. To participate in SBLF, a Bank must be less than $10 billion in size and qualifying credits must be less than $10 million to companies with less than $50 million in sales. The SBLF program encourages growth in loans and allows its participants to capitalize on potential rate reductions well below those established under the TARP program. Subject to final regulatory approval from the Federal Reserve and final due diligence by the Treasury, First Merchants expects the closing of its SBLF investment to occur within the next two weeks.

Michael C. Rechin, President and Chief Executive Officer said, “The completion of this transaction when coupled with the strengthening of First Merchants Bank serves as a catalyst for our future. We are poised to capitalize on core organic growth and acquisition growth without an overhang in our stock price. First Merchants is a transformed company with a rich heritage in its most established markets and a strong foothold in its higher growth markets with attractive demographic profiles.” Rechin also added, “Our focus has always been small business and the middle market, so the SBLF program fits First Merchants very well. We are a small business commercial bank per the SBLF definition and we are proud to serve our customers in such a capacity. We understand that we need our communities as much as they need us. It’s a partnership and it provides for a bright future for our employees, customers and shareholders.”

The repayment of the TARP investment in full will result in the reversal of last year’s gain resulting from favorable accounting treatment attributable to the exchange of designated preferred securities for trust preferred securities as reported on form 10-k on July 2, 2010.

FIG Partners served as a financial advisor to First Merchants on the above private equity offering.

About First Merchants Corporation

First Merchants Corporation is a financial holding company headquartered in Muncie, Indiana. The Corporation is comprised of First Merchants Bank, N.A., which also operates as Lafayette Bank & Trust, Commerce National Bank, and First Merchants Trust Company as divisions of First Merchants Bank, N.A. First Merchants Corporation also operates First Merchants Insurance Group, a full-service property casualty, personal lines, and healthcare insurance agency.

First Merchants Corporation’s common stock is traded on the NASDAQ Global Select Market System under the symbol FRME. Quotations are carried in daily newspapers and can be found on the company’s Internet web page (http://www.firstmerchants.com).

ParkerVision (PRKR) Signs Purchase Agreement for Common Stock

JACKSONVILLE, Fla., Sept. 9, 2011 (GLOBE NEWSWIRE) — ParkerVision, Inc. (Nasdaq:PRKR) (“ParkerVision”) today announced the signing of a securities purchase agreement for the sale of 7,800,000 shares of its common stock at a price of $0.88 per share, in a registered offering to certain institutional investors. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE Amex:LTS), is acting as the placement agent for the offering.

Upon closing, net proceeds from the sale of the shares, after deducting the placement agent’s fees and the other offering expenses, are expected to be approximately $6.5 million. The offering is subject to customary closing conditions and is expected to close on or about September 14, 2011. The Company plans to use the net proceeds from the offering for working capital and for other general corporate purposes, including funding its research, its sales and marketing activities and its infringement litigation.

The offering is being made pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission on September 14, 2009. Copies of the prospectus supplement and accompanying base prospectus relating to the offering may be obtained from the Securities and Exchange Commission at http://www.sec.gov, or from Ladenburg Thalmann & Co. Inc., 4400 Biscayne Blvd., 14th Floor, Miami, FL 33137, or by calling (305) 572-4200.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the shares of common stock, nor shall there be any sale of the shares of common stock in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of the shares under the securities laws of any such state or jurisdiction.

About ParkerVision, Inc.

ParkerVision designs, develops and sells its proprietary RF technologies which enable advanced wireless communications for current and next generation mobile communications networks. ParkerVision is headquartered in Jacksonville, Florida.

The ParkerVision, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7219

Safe Harbor Statement

This press release contains forward-looking information. Readers are cautioned not to place undue reliance on any such forward-looking statements, each of which speaks only as of the date made. Such statements are subject to certain risks and uncertainties which are disclosed in ParkerVision’s SEC reports, including the Form 10-K for the year ended December 31, 2010, and the Forms 10-Q for the quarters ended March 31 and June 30, 2011. These risks and uncertainties could cause actual results to differ materially from those currently anticipated or projected.

CONTACT: ParkerVision, Inc.
         Cindy Poehlman, Chief Financial Officer
         904-732-6100
         cpoehlman@parkervision.com

         The Wall Street Group, Inc.
         Ron Stabiner, Vice President
         212-888-4848
         rstabiner@thewallstreetgroup.com

China Botanic (CBP) Schedules Conference Call to Discuss FY 2011 Third Quarter Results

HARBIN, China, Sept. 9, 2011 /PRNewswire-Asia/ — China Botanic Pharmaceutical Inc. (AMEX: CBP) (“China Botanic” or the “Company”), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines (“TCM”), today announced that it will host a conference call at 9:00 a.m. Eastern Time on Thursday, September 15, 2011, to discuss financial results for the third quarter of fiscal year 2011 ended July 31, 2011.

Joining Mr. Shaoming Li, China Botanic’s chairman and CEO, will be Mr. Guangtao Li, the Company’s vice president and Mr. David Dong, the Company’s CFO.

To participate in the conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: 866-394-2209. International callers should dial +1 706- 758-1481. The conference ID number for the call is 97912567.

If you are unable to participate in the call at this time, a replay will be available on Thursday, September 15, 2011 at 12:00 noon Eastern Time, through Thursday, September 29, 2011. To access the replay, dial 855-859-2056. International callers should dial +1 404-537-3406. The conference ID number for the replay is 97912567.

ABOUT CHINA BOTANIC PHARMACEUTICAL INC.

China Botanic Pharmaceutical Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines (“TCM”), in the People’s Republic of China. All of the Company’s products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China.

VistaGen Therapeutics, Inc. (VSTA) Able to Use Non-Embryonic Stem Cells for Rescuing Promising Drug Candidates

Few advances in the history of human health have raised as much hope as the development and application of pluripotent stem cell technology. It’s an enthusiasm based on the fact that pluripotent stem cells, unlike adult cells, have the remarkable ability, under the right conditions, to be transformed into all sorts of different cells, which can then be used for more efficient research, testing, and ultimately the replacement of damaged tissues and cells for the treatment of heart failure, Parkinson’s disease, cancer, and other life threatening conditions. A key point is that there are different kinds of stem cells, though with similar capabilities.

Embryonic Stem Cells (ES Cells) are pluripotent stem cells derived from excess embryos, eggs that have been fertilized in vitro (IVF) and donated for research purposes with the informed consent of the donors. These embryos did not develop inside the body, and consist of only about 100 cells, long before organs, tissues, or nerves have developed. ES Cells have well-documented potential to differentiate into any of the over 200 cell types found in the human body (that is, they are pluripotent).

Induced Pluripotent Stem Cells (iPS Cells) are derived from adult cells, typically human skin or fat cells, that have been genetically reprogrammed to behave like ES Cells. This is done by forcing the cells to express the genes necessary for maintaining the differentiating ability found in ES Cells. Although ES Cells and iPS Cells are similar in many respects, including the important ability to differentiate into other types of cells, scientists are still determining if there some ways in which they are not alike.

VistaGen Therapeutics is a biotechnology company primarily focused on using advanced stem cell technologies for rescuing previously researched drugs. These are drugs that may have had millions of dollars in research behind them, with proven efficacy, but were blocked because of possible toxicity issues, usually heart or liver toxicity. In some cases this is due simply to the inability of existing assays to provide adequate toxicity data. Such drugs offer immense potential if they can be brought back to life through today’s state-of-the-art testing methods being made possible by VistaGen’s proprietary pluripotent stem cell technologies.

For example, VistaGen’s human heart cell bioassay system, CardioSafe 3D, can provide clearly predictive heart toxicity data on drug candidates before they are ever tested in humans. CardioSafe 3D is based upon a combination of proprietary and exclusively licensed stem cell technologies, including technologies developed over the last 20 years by renowned Canadian scientist, Dr. Gordon Keller, and Dr. Ralph Snodgrass, VistaGen’s founder, President and Chief Scientific Officer. It’s a superior approach designed to eliminate the possibility of toxicity surprises such as occurred with Merck’s Vioxx or GlaxoSmithKline’s Avandia.

VistaGen’s additional advantage is that the Company has developed the ability to use iPS Cells as well as ES Cells for their applications, and in fact has not had to use excess embryos from IVF clinics for over 7 years.

Evolution Petroleum (EPM) Reports Fourth Quarter and Fiscal Year 2011 Financial Results, Reserves and Operations Update

Quepasa (QPSA) Announces 4.4 MM Installs of Wonderful City – Rio

WEST PALM BEACH, FL — (Marketwire) — 09/07/11 — Quepasa Corporation (NYSE Amex: QPSA), owner of popular Latino online social network Quepasa.com and social game development studio Quepasa Games, today announced that its first proprietary social gaming title, Wonderful City – Rio, achieved 4.4 million installs, delivering over 1.1 million new installs in August alone. Quepasa management discussed plans to aggressively grow the title’s user base, while strategically targeting geographies with high monetization potential and expanding into key international markets.

As of August 31st, the game’s global install base totaled 4.4 million, representing 26% growth on a month-over-month basis. This includes 862,000 DAUs, or Daily Active Users, and nearly 4.0 million MAUs, or Monthly Active Users. In addition to Wonderful City’s August results, Quepasa highlighted that the title established strong momentum in certain markets outside of Latin America — namely Spain and Portugal — suggesting potential to capture a broader global audience within the Facebook platform.

“Wonderful City’s Rio theme is demonstrating its global appeal and we see great potential to significantly expand our user base by both marketing more consistently to our core Latin demographic and extending our footprint to other high growth markets,” stated Quepasa CEO John C. Abbott.

Quepasa highlighted some key data and trends specific to the game’s performance on each of the three platforms, including:

• Facebook: Momentum continued to be strong with over 550,000 installs in August, bringing total Facebook users to 1.3 million, an increase of 40% since the end of July.
• Orkut: Installs grew by over 560,000 in August, bringing total Orkut users to 2.8 million, a 25% increase since the end of July. In addition, the Orkut platform maintained strong user engagement metrics, including 677,000 DAUs and 2.6 million MAUs for a DAU/MAU ratio of 25.9%.
• Quepasa: Revenues saw improvement following the implementation of a new pricing strategy, which was then rolled out on both Facebook and Orkut at the beginning of September.

In the month of August, Quepasa.com’s registered user base grew to a total of 39.1 million members, adding 425,000 new members. The site generated 202 million page views and 17 million unique visits. Quepasa management highlighted key near-term opportunities for improvement in Quepasa.com’s top line metrics, including the continued rebound in email volume, a key driver for both acquisition and retention that saw a 20% increase over the course of August, as well as progress in its ongoing collaboration with myYearbook towards improving site retention. Management cited positive early results from this effort, including nearly doubling usage of Quepasa’s “Papacito,” a social discovery application similar to myYearbook’s “Match” application, a 37% increase in messages sent and a 25% increase in new friendships created between members. These important engagement metrics were complemented by an overall 2% increase in the site’s DAU/MAU ratio, representing a 27% year-over-year gain.

Investor Relations Updates
As a part of ongoing investor relations campaigns, Quepasa will be presenting at the following industry conferences during the month of September:

September 7, 2011:   Wedbush's Second Internet Conference, Santa Monica,
                     California
                     http://www.wedbush.com/services/cmg/equities-division/
                     mgmt-access-events

September 12, 2011:  Rodman  Renshaw's Annual Global Investment Conference,
                     New York
                     http://www.rodmanandrenshaw.com/conferences?categoryid
                     =30

September 14, 2011:  ThinkEquity's G8 Public Company Conference, New York
                     http://www.thinkequity.com/about/conf_calendar.html

CEO John Abbott will webcast live from the ThinkEquity G8 Public Company Conference at 9:30 am ET on September 14, at the following link: Webcast Link: http://wsw.com/webcast/tep21/qpsa/.

In an effort to better engage with the investor community, Quepasa is launching a Social Media Outreach program via new accounts on both StockTwits.com and Twitter.com. Follow progress at “QuepasaCorp” on StockTwits and Twitter for updates on advertising campaigns on Quepasa Contests, corporate events, other relevant industry trends and information, and updates on Quepasa Games.

About Quepasa Corporation
Quepasa Corporation (NYSE Amex: QPSA) is a social media technology company focused on Latin audiences worldwide. Quepasa owns and operates Quepasa.com, a leading social networking website, Quepasa Games, a social gaming studio, and Quepasa Contests, a cross platform social media advertising solution. Quepasa brings the best of the social web to over 40 million global users, inviting them to play, flirt and win through fun and distinctly Latin online experiences. Quepasa is headquartered in West Palm Beach, Florida with offices in Los Angeles, California, Hermosillo, Mexico, and Curitiba, Brazil. For more information about the company, go to www.quepasacorp.com.

Cautionary Note Concerning Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding plans to aggressively grow the title’s user base, targeting geographies with high monetization potential and expanding into key international markets, momentum and potential to capture a broader global audience with the Facebook platform, potential to expand our user base, and opportunities to improve top line metrics. All statements other than statements of historical facts contained in this press release, including statements regarding our future financial position, liquidity, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Important factors that could cause actual results to differ from those in the forward-looking statements include competition with other social games, acceptance by a global audience of our game titles, and unanticipated problems which lead Facebook, Orkut and other social media platforms to not publish our games. Further information on our risk factors is contained in our filings with the SEC, including the Form S-4 filed on August 26, 2011 and our Form 10-K for the year ended December 31, 2010. Any forward-looking statement made by us in this press release speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Additional Information
This communication does not constitute an offer to sell or the solicitation of an offer to buy Quepasa’s securities or the solicitation of any shareholder vote or approval. This communication is being made in respect of the proposed transaction involving Quepasa and Insider Guides. In connection with the proposed transaction, Quepasa has filed with the SEC a registration statement on Form S-4 that includes a proxy statement and prospectus of Quepasa. Before making any voting or investment decision, investors and shareholders are urged to read carefully the proxy statement and prospectus regarding the proposed transaction and any other relevant documents filed by Quepasa with the SEC because they contain important information about the proposed transaction. You may obtain copies of all documents filed with the SEC regarding this transaction, free of charge, at the SEC’s website (www.sec.gov), by accessing Quepasa’s website at www.quepasacorp.com under the heading “Investors” and then under the link “SEC Filings” and from Quepasa by directing a request to Quepasa at Quepasa Corporation, 324 Datura Street, Suite 114, West Palm Beach, FL 33401, Attention: Investor Relations.

Quepasa and its directors and executive officers and certain other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. You can find information about Quepasa’s directors and executive officers in its definitive proxy statement filed with the SEC on April 14, 2011. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement and prospectus and other relevant materials filed with the SEC. You can obtain free copies of these documents from Quepasa using the contact information above.

Company Contact:
E. Brian Harvey
Vice President of Capital Markets and Investor Relations
Quepasa Corporation
Tel (310) 801-1719
brian.harvey@quepasacorp.com

FuelCell Energy (FCEL) Announces Asian Market Expansion With Sale of Ultra-Clean Fuel Cell Module

DANBURY, Conn., Sept. 7, 2011 (GLOBE NEWSWIRE) — FuelCell Energy, Inc. (Nasdaq:FCEL) a leading manufacturer of ultra-clean, efficient and reliable power plants, today announced market expansion into Indonesia with the sale of a sub-megawatt Direct FuelCell® (DFC®) module to partner POSCO Power for installation at a showcase location in Indonesia. POSCO Power will combine the fuel cell module with locally manufactured balance of plant and install the complete fuel cell power plant at a heavily visited waterpark resort in Jakarta, Indonesia. This high exposure installation will demonstrate the benefits of ultra-clean, efficient and reliable power generation as POSCO Power develops a market for megawatt class power plants in Southeast Asia, starting with Indonesia and to be followed by Thailand, Malaysia and Singapore.

“Establishing a presence in Jakarta, Indonesia with a Direct FuelCell power plant is the first overseas expansion for POSCO Power and is the first commercial stationary fuel cell power plant to be installed in Southeast Asia outside of South Korea,” said Soung-Sik Cho, Chief Executive Officer for POSCO Power. “I am pleased to be leading POSCO Power as the organization moves from a technology importer to a green and high-tech ambassador of ultra-clean and efficient fuel cell power generation in Asia.”

Indonesia is the fourth most populous country in the world with a population of approximately 245 million and is the world’s eighth largest producer of natural gas. With growing power needs from an expanding urban middle class, Indonesian utilities need scalable baseload distributed generation. The virtual lack of emissions combined with quiet operation of DFC plants, facilitates their siting in populated areas. The scalable nature of DFC plants permits utilities to add power in cost effective increments as demand warrants. Distributed generation also improves energy security and energy reliability while reducing the need to build and maintain costly transmission and distribution.

“POSCO Power has ordered 140 megawatts of ultra-clean Direct FuelCell power plants and fuel cell components since 2007,” said Chip Bottone, President and CEO for FuelCell Energy, Inc. “With this strong market development base of expertise and having developed strong ties with the Indonesian Government, POSCO Power is well positioned to build on their success in South Korea with fuel cell power plant exports throughout Indonesia and Southeast Asia.”

DFC plants are fuel flexible, operating on natural gas or renewable biogas. Given Indonesia’s abundant supplies of domestic natural gas and desire to reduce pollutants and carbon emissions, DFC plants are an attractive power generation solution for Indonesian utilities and independent power producers. Fuel cells generate electricity cleanly and efficiently using an electrochemical process that does not involve combustion. The lack of combustion eliminates almost all pollutants such as NOx, SOx or particulate matter.

DFC plants are 47 percent electrically efficient, which is higher than any other power generation of a similar size. High efficiency results in fuel savings as a greater amount of electricity is generated from each unit of fuel and high efficiency also reduces carbon emissions, helping customers reach sustainability goals. In addition to ultra-clean power, DFC plants generate usable high quality heat suitable for generating steam and can achieve efficiencies up to 90 percent in a combined heat and power (CHP) configuration. The heat from this power plant is expected to be used for facility heating and cooling.

As the market in Indonesia and Southeast Asia develops, FuelCell Energy will build and export the core fuel cell components to South Korea where POSCO Power will stack the components to create fuel cell modules. The modules will be combined with locally built or sourced balance of plant and the completed DFC plant will be shipped to Indonesia. In addition to the revenue generated from the sale of components, POSCO Power will pay a royalty to FuelCell Energy for each complete power plant built under a 2009 licensing agreement.

The 300 kilowatt DFC300 power plant is expected to be operating by the end of 2012 at Ancol Dreamland resort in Jakarta, Indonesia, one of the most highly visited tourist destinations in Southeast Asia.

About FuelCell Energy

Direct FuelCell® power plants are generating ultra-clean, efficient and reliable power at more than 50 locations worldwide. The Company’s power plants have generated over 850 million kWh of power using a variety of fuels including renewable biogas from wastewater treatment and food processing, as well as clean natural gas. With over 180 megawatts of power generation capacity installed or in backlog, FuelCell Energy is a global leader in providing ultra-clean baseload distributed generation to utilities, industrial operations, universities, municipal water treatment facilities, government installations and other customers around the world. For more information please visit our website at www.fuelcellenergy.com

This news release contains forward-looking statements, including statements regarding the Company’s plans and expectations regarding the continuing development, commercialization and financing of its fuel cell technology and business plans. All forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause such a difference include, without limitation, general risks associated with product development, manufacturing, changes in the regulatory environment, customer strategies, potential volatility of energy prices, rapid technological change, competition, and the Company’s ability to achieve its sales plans and cost reduction targets, as well as other risks set forth in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements contained herein speak only as of the date of this press release. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in the Company’s expectations or any change in events, conditions or circumstances on which any such statement is based.

Direct FuelCell, DFC, DFC/T, DFC-H2 and FuelCell Energy, Inc. are all registered trademarks of FuelCell Energy, Inc. DFC-ERG is a registered trademark jointly owned by Enbridge, Inc. and FuelCell Energy, Inc.

CONTACT: FuelCell Energy, Inc.
         Kurt Goddard, Vice President Investor Relations
         203-830-7494
         ir@fce.com

Conn’s, Inc. (CONN) Reports Results for the Quarter Ended July 31, 2011

VistaGen Therapeutics Inc. (VSTA) on Path to Higher Exchange

Like a number of other growing companies, VistaGen Therapeutics, a biotech company applying stem cell technology for drug rescue and cell therapy, plans to use the OTC Bulletin Board as an important starting point for a move to the NYSE Amex or NASDAQ. In its efforts to access capital markets and raise awareness, the company sees such a move as important for expanding visibility and growing its investor base. Biotech companies that have recently followed a similar path include Neoprobe Corp. (NEOP), which successfully made the leap from OTCBB to the NYSE Amex earlier this year, and Echo Therapeutics (ECTE), which recently moved from the OTCBB to Nasdaq. [NOTE: ECTE reflects the march to Nasdaq very well, and its post-listing volume is much more reflective of what VistaGen aspires to achieve near term.]

Following its successful strategic financing in May, VistaGen is now ready to put its advanced stem cell technology platform to work after twelve years of extensive research and development. VistaGen’s platform combines several technologies, including stem cell technologies developed by VistaGen and renowned Canadian scientist, Dr. Gordon Keller, the Chairman of VistaGen’s Scientific Advisory Board and Director of the University Health Network’s McEwen Centre for Regenerative Medicine in Toronto. One valuable commercial application of VistaGen’s technology involves using mature human cells derived from pluripotent stem cells to create a new generation of biological assays for drug screening. It’s part of an effort to rescue once promising drug candidates that have proven efficacy but which were shelved by pharmaceutical companies due to toxicity issues.

VistaGen’s first target market is heart toxicity, an area of primary concern and potential. The Company’s human heart cell-based CardioSafe 3D bioassay system provides clinically relevant predictive data before human use, thereby preventing serious safety problems seen with such widely-marketed products as Merck’s Vioxx or GlaxoSmithKline’s Avandia. VistaGen is looking to rescue drug candidates that have established efficacy and millions dollars in research behind them, offering huge potential when brought back on track through carefully performed re-engineering using a combination of its stem cell technology and modern medicinal chemistry.

Besides drug rescue, VistaGen is also using its stem cell technologies to advance its preclinical cell therapy programs for applications in autologous bone marrow transplantation and heart, liver, and cartilage repair. In addition, its AV-101 prodrug candidate is in clinical development for treatment of neuropathic pain and other neurological disorders such as epilepsy, and Parkinson’s disease and depression.

For additional information, visit the company’s website at www.VistaGen.com